Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O’Riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha-Lavsky, Jeffrey M. Saland, William G. van’t Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Simkova, Jaap W. Groothoff, David J. Sas, Kristin A. Meliambro, Jiandong Lu, Marianne T. SweetserPushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1'. Together they form a unique fingerprint.

Medicine & Life Sciences